Shares of MannKind Corporation (NASDAQ:MNKD) ended Thursday session in red amid volatile trading. The shares closed down -0.004 points or -0.60% at $0.681with 3.84 million shares getting traded. Post opening the session at $0.69, the shares hit an intraday low of $0.67 and an intraday high of $0.70 and the price vacillated in this range throughout the day. The company has a market cap of $319.49 million and the numbers of outstanding shares have been calculated to be 478.05 million shares.
MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes patients in the United States. Its approved product is AFREZZA, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. MannKind Corporation has license and collaboration agreement with Sanofi-Aventis Deutschland GmbH for the development of AFREZZA. The company was founded in 1991 and is headquartered in Valencia, California.
Shares of Express Scripts Holding Company (NASDAQ:ESRX) ended Thursday session in green amid volatile trading. The shares closed up +1.38 points or 1.98% at $71.03 with 3.82 million shares getting traded. Post opening the session at $70.03, the shares hit an intraday low of $69.82 and an intraday high of $71.85 and the price vacillated in this range throughout the day. The company has a market cap of $43.89 billion and the numbers of outstanding shares have been calculated to be 630.22 million shares.
Express Scripts Holding Company (ESRX) on Sept. 8, 2016 launched its Inflammatory Conditions Care Value Program, a comprehensive approach to control costs and improve care for people with inflammatory conditions like rheumatoid arthritis, psoriasis and Crohn’s Disease.
Through the combination of indication-specific formulary management and refunds for early discontinuation of therapy, this new program is the nation’s most comprehensive approach to better align a drug’s price with the value that drug provides a patient.
“Painful inflammatory conditions like rheumatoid arthritis can cripple patients and obliterate payer budgets,” said Glen Stettin, MD, Senior Vice President and Chief Innovation Officer at Express Scripts. “By finding creative ways to take better care of patients and protect our clients’ budgets, Express Scripts is uniquely tackling one of the biggest health challenges facing our country.”
Approximately ten million Americans live with an inflammatory condition. The biologic medications used to treat these conditions became the country’s costliest therapy class in 2015, representing 9.8 percent of all U.S. pharmacy spending. Express Scripts forecasts that, left unchecked, total U.S. spending on these medications will nearly double from 2015 to 2018.